Annotation Detail
Information
- Associated Genes
- ROS1
- Associated Variants
- ROS1 CD74-ROS1 G2032R
- Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo and in enzyme assays. PF-06463922 showed inhibition of kinase activity, cell viability and tumor growth in wild-type, G2032R and L2026M mutations in ROS1.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1251
- Gene URL
- https://civic.genome.wustl.edu/links/genes/4941
- Variant URL
- https://civic.genome.wustl.edu/links/variants/465
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Lorlatinib
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 25733882
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Lorlatinib | Sensitivity | true |